You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Phenoxybenzamine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for phenoxybenzamine hydrochloride and what is the scope of freedom to operate?

Phenoxybenzamine hydrochloride is the generic ingredient in two branded drugs marketed by Concordia, Amneal, Aurobindo Pharma, Endo Operations, Hikma, Novitium Pharma, and Rising, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for phenoxybenzamine hydrochloride. Seven suppliers are listed for this compound.

Summary for phenoxybenzamine hydrochloride
US Patents:0
Tradenames:2
Applicants:7
NDAs:7
Drug Master File Entries: 6
Finished Product Suppliers / Packagers: 7
Raw Ingredient (Bulk) Api Vendors: 104
Clinical Trials: 7
Patent Applications: 988
What excipients (inactive ingredients) are in phenoxybenzamine hydrochloride?phenoxybenzamine hydrochloride excipients list
DailyMed Link:phenoxybenzamine hydrochloride at DailyMed
Recent Clinical Trials for phenoxybenzamine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Seoul National University HospitalPhase 4
University of California, Los AngelesPhase 3
IsalaPhase 4

See all phenoxybenzamine hydrochloride clinical trials

Pharmacology for phenoxybenzamine hydrochloride
Medical Subject Heading (MeSH) Categories for phenoxybenzamine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for phenoxybenzamine hydrochloride

US Patents and Regulatory Information for phenoxybenzamine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations PHENOXYBENZAMINE HYDROCHLORIDE phenoxybenzamine hydrochloride CAPSULE;ORAL 204522-001 Jan 24, 2017 AB RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hikma PHENOXYBENZAMINE HYDROCHLORIDE phenoxybenzamine hydrochloride CAPSULE;ORAL 201050-001 Jul 16, 2012 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Concordia DIBENZYLINE phenoxybenzamine hydrochloride CAPSULE;ORAL 008708-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Rising PHENOXYBENZAMINE HYDROCHLORIDE phenoxybenzamine hydrochloride CAPSULE;ORAL 204551-001 Jun 20, 2023 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Aurobindo Pharma PHENOXYBENZAMINE HYDROCHLORIDE phenoxybenzamine hydrochloride CAPSULE;ORAL 215600-001 May 8, 2023 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Phenoxybenzamine hydrochloride Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Phenoxybenzamine Hydrochloride

Introduction

Phenoxybenzamine hydrochloride is a noncompetitive, nonselective α-adrenergic receptor antagonist primarily used in the management of pheochromocytoma and, in some cases, septic shock. This article delves into the market dynamics and financial trajectory of this drug, providing insights into its current market status, future projections, and the factors influencing its use and revenue.

Current Market Status

Global Market Size

The global phenoxybenzamine hydrochloride market was valued at approximately USD 145 million in 2023. This figure indicates a niche but significant market presence for a drug that is specialized in treating specific conditions[4].

Regional Market

The North American market for phenoxybenzamine hydrochloride is expected to grow from its current value to a projected figure by 2030, with a compound annual growth rate (CAGR) during this period. This growth is driven by the increasing need for effective treatments for pheochromocytoma and other related conditions[1].

Market Growth Drivers

Clinical Use and Indications

Phenoxybenzamine hydrochloride is primarily indicated for the treatment of pheochromocytoma, a rare tumor of the adrenal gland that can cause severe hypertension and other symptoms. Its effectiveness in controlling episodes of hypertension and sweating makes it a crucial drug in this therapeutic area[5].

Unmet Medical Needs

The drug's nomination for inclusion on the 503B Bulks List by Fagron highlights the unmet medical need for an intravenous formulation, as it is not commercially available. This gap in the market drives demand and potential growth for phenoxybenzamine hydrochloride[2].

Financial Projections

Market Size Projections

The global market for phenoxybenzamine hydrochloride is projected to reach approximately USD 220 million by 2032. This growth is anticipated due to increasing awareness and diagnosis of pheochromocytoma, as well as advancements in healthcare infrastructure and access to specialized treatments[4].

Revenue Growth

The revenue growth of phenoxybenzamine hydrochloride is expected to be steady, driven by the consistent demand for this specialized medication. The CAGR for the North American market, while not specified, is indicative of a growing market that is expected to expand over the next several years[1].

Regulatory and Availability Factors

FDA Considerations

The nomination of phenoxybenzamine hydrochloride for the 503B Bulks List by the FDA is a significant factor in its market dynamics. This nomination is based on the drug's clinical use and the need for its availability in compounding by outsourcing facilities. The FDA's evaluation and potential inclusion on this list could further stabilize and grow the market[2].

Global Availability

Phenoxybenzamine hydrochloride's availability varies globally. A search of national medicine registers in 13 countries and regions showed that the drug is not widely available in all markets, which can impact its global market size and growth potential[2].

Competitive Landscape

Generic and Branded Products

The market for phenoxybenzamine hydrochloride is influenced by the dynamics of generic and branded pharmaceuticals. While there is no commercial intravenous formulation available, the presence of other adrenergic receptor antagonists could impact market share. However, the specialized nature of phenoxybenzamine hydrochloride maintains its unique position in the market[2].

Pricing and Reimbursement

Drug Expenditure Dynamics

The overall drug expenditure dynamics, including discounts and rebates, play a crucial role in the financial trajectory of phenoxybenzamine hydrochloride. The trend of increasing net per capita drug spending, albeit with a slower growth in manufacturer net revenue, suggests that pricing strategies and reimbursement policies will be critical in determining the drug's market performance[3].

Challenges and Risks

Safety and Efficacy Concerns

Phenoxybenzamine hydrochloride has been associated with several safety concerns, including carcinogenic potential and mutagenic activity. These risks necessitate careful consideration and monitoring, which can impact long-term market growth and acceptance[5].

Regulatory Risks

The regulatory environment, particularly the FDA's evaluation and potential inclusion on the 503B Bulks List, poses both opportunities and risks. Any adverse regulatory decisions could negatively impact the drug's market trajectory[2].

Conclusion

Phenoxybenzamine hydrochloride's market dynamics are characterized by a growing demand driven by its specialized use in treating pheochromocytoma and other conditions. The financial trajectory is projected to be positive, with a significant increase in market size expected over the next decade. However, the market is also influenced by regulatory considerations, safety concerns, and the broader dynamics of pharmaceutical spending.

Key Takeaways

  • The global phenoxybenzamine hydrochloride market is valued at approximately USD 145 million in 2023 and is projected to reach USD 220 million by 2032.
  • The North American market is expected to grow at a steady CAGR.
  • The drug's primary indication is for the treatment of pheochromocytoma.
  • Regulatory considerations, including the FDA's evaluation for the 503B Bulks List, are crucial for market growth.
  • Safety concerns and regulatory risks need to be carefully managed.

FAQs

What is the primary use of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride is primarily used in the treatment of pheochromocytoma to control episodes of hypertension and sweating.

What is the current global market size for phenoxybenzamine hydrochloride?

The global market size for phenoxybenzamine hydrochloride was valued at approximately USD 145 million in 2023.

What are the projected market size and growth for phenoxybenzamine hydrochloride?

The global market is projected to reach approximately USD 220 million by 2032, with a steady growth rate.

Why is phenoxybenzamine hydrochloride nominated for the 503B Bulks List?

Phenoxybenzamine hydrochloride was nominated for the 503B Bulks List due to the unmet medical need for an intravenous formulation, which is not commercially available.

What are the safety concerns associated with phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride has been associated with carcinogenic potential, mutagenic activity, and other safety concerns that necessitate careful monitoring and consideration.

Sources

  1. Valuates Reports: Phenoxybenzamine Hydrochloride Market.
  2. University of Maryland, Baltimore: Phenoxybenzamine hydrochloride Summary Report.
  3. IQVIA: Drug Expenditure Dynamics 1995-2020.
  4. DataIntelo: Phenoxybenzamine Hydrochloride Market Research Report 2032.
  5. DailyMed: PHENOXYBENZAMINE HYDROCHLORIDE capsule.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.